SR MEDICAL (00108) has released its interim results for the six months ended June 30, 2026, reporting revenue of HK$223 million, marking a year-on-year increase of approximately 30.7%.

The company recorded a loss attributable to shareholders of HK$70.601 million, compared to a profit of HK$2.091 million in the same period last year, with a basic loss per share of 2.18 HK cents.

According to the announcement, the loss for the period is primarily attributed to increased other operating costs, higher finance expenses, and elevated employee benefit costs compared to the same period in 2025, partially offset by the revenue growth resulting from the completion of the acquisition of the acquired company and the full-scale operation of the Culver City integrated property.